Company / Revenue per Share
Esperion Therapeutics, Inc. Revenue per Share History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue per Share
$1.94
FY2025
5-year range
$1.13 / $2.90
FY2021-FY2025
Trend
+9.2%
vs FY2024
Sector context
#90 of 154
Health Care
What the data says
At $1.94, Esperion Therapeutics, Inc.'s revenue per share ranks #90 of 154 in the Health Care sector. Improved from $1.13 to $1.94 over the past 2 years.
Based on SEC 10-K filings.
1.94 in FY2025 with a 5-year CAGR of -25.2%.
Improved from $1.13 to $1.94 over the past 2 years.
Health Care sector context is included.
Revenue per Share over time
Growth rates
- 3-Year CAGR
- +19.5%
- 5-Year CAGR
- -25.2%
- 10-Year CAGR
- -
Sector benchmark
#90 of 154 in Health CareTop 58% of 154This company $1.94 Sector average $15.09
▼
-87.1% below sector average
Key checks
Key Insights
- In FY2025, revenue per share increased 9.2% year-over-year.
- Ranks #90 out of 154 companies in the Health Care sector.
- Peak revenue per share was recorded in FY2020.
- Lowest revenue per share in the period was in FY2018.
Company context
Key Data Points
- Altman Z-Score -1.60 (distress zone, below 1.8 threshold)
- Negative profit margin: -15.6%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Revenue per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.94 | +9.2% |
| FY2024 | $1.78 | +57.3% |
| FY2023 | $1.13 | -0.7% |
| FY2022 | $1.14 | -60.8% |
| FY2021 | $2.90 | -65.0% |
| FY2020 | $8.28 | +49.6% |
| FY2019 | $5.53 | - |
| FY2018 | $0.00 | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026